Cognitive dysfunction and associated neuroimaging biomarkers in antiphospholipid syndrome: a systematic review
Authors:
Open Access
- 18 May 2021
- journal article
- review article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 61 (1) , 24-41
Abstract
Objectives: Cognitive dysfunction is common in patients with aPL (including primary APS or APS associated with SLE). Neuroimaging biomarkers may contribute to our understanding of mechanisms of cognitive dysfunction in these cohorts. This review aimed to investigate: (i) the prevalence of cognitive dysfunction in studies including neuroimaging biomarkers; and (ii) associations between cognition and neuroimaging biomarkers in patients with APS/aPL. Methods: We conducted a systematic search of electronic databases PubMed, Science Direct, Scopus and PsycINFO, and included studies with descriptions of neuroimaging findings, cognitive dysfunction or both, in patients with aPL positivity (LA, IgG and IgM aCL and anti-β2 glycoprotein-I antibodies). Results: Of 120 search results we included 20 eligible studies (6 APS, 4 SLE with APS/aPL and 10 NPSLE). We identified a medium risk of bias in 6/11 (54%) of cohort studies and 44% of case–control studies, as well as marked heterogeneity in cognitive assessment batteries, APS and aPL definitions, and neuroimaging modalities and protocols. The prevalence of cognitive dysfunction ranged between 11 and 60.5%. Structural MRI was the most common imaging modality, reporting cognitive dysfunction to be associated with white matter hyperintensities, ischaemic lesions and cortical atrophy (four with cerebral atrophy, two with white matter hyperintensities and two with cerebral infarcts). Conclusion: Our findings confirm that cognitive impairment is commonly found in patients with aPL (including APS, SLE and NPSLE). The risk of bias, and heterogeneity in the cognitive and neuroimaging biomarkers reported does not allow for definitive conclusions.Keywords
This publication has 57 references indexed in Scilit:
- Neuropsychiatric manifestations in patients with systemic lupus erythematosus: epidemiology and radiology pointing to an immune-mediated causeAnnals of the Rheumatic Diseases, 2013
- Neurological manifestations of antiphospholipid syndromeEuropean Journal of Clinical Investigation, 2010
- Moderate versus high-titer persistently anticardiolipin antibody positive patients: Are they clinically different and does high-titer anti-β2-glycoprotein-I antibody positivity offer additional predictive information?Lupus, 2009
- Comparison of the Clinical Manifestations, Brain MRI and Prognosis between NeuroBehçet's Disease and Neuropsychiatric LupusThe Korean Journal of Internal Medicine, 2007
- Valvular Heart Disease Is Associated With Nonfocal Neuropsychiatric Systemic Lupus ErythematosusJCR: Journal of Clinical Rheumatology, 2006
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- Ethnic and geographical variation in antiphospholipid (Hughes) syndromeAnnals of the Rheumatic Diseases, 2005
- Hughes Syndrome, the Antiphospholipid Syndrome: A New Chapter in NeurologyAnnals of the New York Academy of Sciences, 2005
- International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshopArthritis & Rheumatism, 1999
- Cognitive decline strongly correlates with cortical atrophy in Alzheimer’s dementiaNeurobiology of Aging, 1998